AQST Aquestive Corp: Enterprise Value to EBITDA Ratio
Aquestive Therapeutics (AQST) maintains moderate financial stability, as revenue depends on patent rights and new releases. This EV/EBITDA chart with historical data visualizes the valuation trend of enterprise value relative to operating profit, while 0.00 reflects the metric's most recent value. Profit is based on the sale of soluble films for allergy and epilepsy therapy. Experienced management is effectively developing a portfolio of innovative drug delivery systems.
Comprehensive metric breakdowns and analytics for aquestive.com (AQST)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Aquestive Therapeutics|AQST - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Aquestive Therapeutics, Inc.|AQST - Company Aggregate Debts|Debt to Book Capitalization Ratio Aquestive Corp|AQST - Long-Term Indebtedness|Company Current Liabilities Aquestive Therapeutics|Quick Ratio aquestive.com
- financial results and valuation multiples details:
AQST - Company Net Income|Expected Profit Aquestive Therapeutics|AQST - Business Payback Period|Projected Price to Earnings Aquestive Therapeutics|AQST - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Aquestive Corp|AQST - Operating income before deduction of amortization|Net earnings per share for the last 12 months Aquestive Therapeutics|AQST - Earnings per share for the last twelve months|Quarterly EPS earnings growth aquestive.com|AQST - Earnings per share growth rate in current year|Expected earnings per share growth for next year Aquestive Therapeutics
- company sales and revenue statistics:
Fundamental company analysis:AQST (Aquestive Pharma)
The specifics of Aquestive Therapeutics (AQST), which depend on stable demand for drugs amid risks of raw material supply chain disruptions, require strict control of debt load. This metric compares the total enterprise value with operating profit, allowing the identification of fundamental asset undervaluation or critical debt levels that determine the company's investment attractiveness through changes in the EV/EBITDA value over time.
Main competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|EV/EBITDA Multiple MannKind Corp MNKD|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Pacira Corp (PCRX)|SPRY (ARS Pharmaceuticals) - Enterprise Value to EBITDA Ratio|theravance.com (TBPH) - EV/EBITDA Multiple|SCPH (scPharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Tectonic TECX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Inc. (TNXP)|Total Company Value to Operating Income Before Depreciation Ratio sxtchina.com|Eupraxia Pharmaceuticals Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio BHST (bioharvest.com)|eXoZymes - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Oramed Pharmaceuticals ORMP|ENTX (enterabio.com) - Enterprise Value to EBITDA Ratio|HYFT (MindWalk Therapeutics) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|Company Value to EBITDA cumberlandpharma.com CPIX|Enterprise Value to EBITDA Ratio QNTM (Quantum BioPharma)|FGEN (FibroGen Inc) - Business Value to Operating Income Before Depreciation|Telomir Pharma - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio RANI (Rani Therapeutics Holdings)|Synergy CHC Corporation - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation RLYB (Rallybio Corporation)|LEXX: EV/EBITDA Multiple|Company Value to EBITDA Pulmatrix Inc (PULM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|APM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple impactbiomedinc.com (IBO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|YCBD (cbdMD Inc.) - Company Value to Operating Income Before Depreciation Ratio|PainReform Limited - EV/EBITDA Multiple|Company Value to EBITDA Altamira Therapeutics|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|optinose.com (OPTN) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PIRS|PROC (Procaps Group) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|Total Company Value to Operating Income Before Depreciation Ratio Qilian International Corp|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|TFFP - Enterprise Value to EBITDA Ratio
